Project Grant R37CA292595
Award Date 8/8/25
Completion Date 7/31/30
Dollars Obligated $297K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Davis, CA, USA
Similar Awards
- The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $670,534 Project Grant to Northwestern University to develop an optical hyperspectral nanoscale chromatin analysis technology for colorectal cancer risk stratification. The goal is to create a screening test to identify patients who harbor advanced adenomas and should undergo colonoscopy, with a target of 99.5% negative predictive value, 95% sensitivity, and 80% specificity for advanced adenomas....
- This $149,394 Project Grant was awarded on August 1, 2025 by the National Cancer Institute (NCI), part of the Department of Health and Human Services, under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394). The grant supports research led by the University of California, Davis to advance the development of targeted radiopharmaceuticals for cancer diagnosis and therapy. Specifically, the research focuses on designing, synthesizing, and optimizing novel molecular imaging...
- The National Cancer Institute (NCI) awarded a $697,198 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the University of California, San Diego (UC San Diego Health) for the project "Optimal Early Colorectal Cancer Screening Initiation" from January 1, 2025 to December 31, 2027. The grant supports research to develop a targeted colorectal cancer screening strategy for adults aged 45-49, with the goal of maximizing screening uptake and...
- The University of California, Davis (UC Davis) was awarded a $615,399 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to develop a novel therapeutic platform for on-demand modulation of the tumor microenvironment. The project aims to utilize a transformable nanoparticle (TNP) platform that can change morphology to selectively accumulate and retain therapeutics at the tumor site, sparing normal tissues. The researchers will develop TNP constructs...
- The National Cancer Institute (NCI), part of the Department of Health and Human Services, awarded a $881,647 Project Grant to Panome Bio Inc. under the Cancer Detection and Diagnosis Research Federal Grant Program (CFDA 93.394). The grant supports research to advance untargeted metabolomics approaches for biomarker discovery in colon cancer. Specifically, Panome Bio is developing novel software and analytical methods to enhance the value and impact of untargeted metabolomics by addressing...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $2,491,138 to Oregon Health & Science University to develop a fluorescence-guided nerve sparing technique for colorectal cancer surgery. The project aims to enable real-time visualization of nerves during surgery using a near-infrared fluorescent contrast agent. This approach seeks to improve surgical outcomes by reducing positive margins and nerve damage, which can...
- This federal Project Grant award, titled "Automated Multi-Timepoint CT Analysis for Enhanced Metastatic Disease Evaluation in Colorectal Cancer: An Anatomy-Aware Vision-Language AI Approach," was provided by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The $718,456 award, with a performance period from July 1, 2025 to May 31, 2029, supports...
- The National Cancer Institute (NCI) has awarded a $572,490 Project Grant to The Regents of the University of California, San Francisco (UCSF) under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394). The project, titled "PILLAR: Multi-Modal Imaging AI Models for Breast Cancer Risk", aims to develop an AI-powered tool to predict breast cancer risk using longitudinal data from mammograms, tomosynthesis, and MRI scans. The goal is to create more accurate cancer risk...
- The National Cancer Institute (NCI) has awarded a $727,904 Cooperative Agreement to The Trustees of Columbia University in the City of New York, doing business as the Health Sciences Division, under the Cancer Biology Research program (CFDA 93.396). The purpose of this 23-month award, with a start date of August 11, 2025, is to engineer probiotic bacteria (E. coli Nissle 1917) to identify precancerous lesions, characterize novel stage-specific immune targets, and design immunomodulatory...
- This federal Project Grant award of $592,866 from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to develop ingestible nanosensors for the early detection of colorectal cancer through breath-based biomarkers. The principal objectives are to engineer nanosensors that can sense specific enzymes associated with tumor development in the intestinal mucosa and release volatile reporters that can be detected in the patient's breath. This non-invasive...